Aim. To develop and apply a risk-based framework for identifying and controlling critical study phases and for assuring data integrity and traceability in an etmaben safety pharmacology study. Materials and methods. The study workflow was decomposed into four functional blocks: organisational and preparatory activities, exposure-forming procedures, primary data-generating procedures, and data processing and reporting. A phase was considered critical when an error could affect test-item exposure, animal or sample identification, the assessment of one or more physiological systems, raw-data traceability, or the final interpretation of the study. For each critical phase, the potential risk, control parameters, supporting records, and actions under the Good Laboratory Practice principles and the quality assurance programme were defined. Criticality was assessed using the risk priority number, RPN = P × D × S, where P represented the probability of an error, D the difficulty of its timely detection, and S the scope of its potential impact on the data. Each criterion was scored on a scale from 1 to 5. RPN values of ≥30, 17–29, and ≤16 was classified as high, medium, and low criticality, respectively. Results. Ten critical phases were identified: study planning; receipt and identification of the test item; animal housing and use; suspension preparation and dose calculation; etmaben administration; recording of physiological endpoints; behavioural and neuromuscular testing; biochemical testing; statistical analysis; and final report preparation and archiving. Eight phases were classified as highly critical and two as moderately critical. The highest RPN values were assigned to etmaben administration (48), recording of physiological endpoints (45), study planning (40), and statistical analysis (40). System-specific critical phases and control parameters were defined for the cardiovascular, respiratory, central nervous and neuromuscular systems, as well as for additional biochemical endpoints. The corresponding GLP actions included study-based and process-based inspections, verification of equipment and personnel records, assessment of raw-data traceability and deviations, and comparison of the final report with the original study records. Conclusion. The proposed framework links each critical phase to a potential risk, a control parameter, a supporting raw record, and an action within the quality assurance programme. This approach supports risk-based planning of quality assurance activities and provides documented traceability of safety pharmacology data from study planning and test-item administration to statistical analysis and final reporting.
safety pharmacology, etmaben, critical phase, data integrity, data traceability, good laboratory practice, quality assurance, risk-based approach, rats
1. International Council for Harmo-nisation of Technical Requirements for Pharmaceuticals for Human Use. Safety pharmacology studies for human phar-maceuticals: ICH harmonised tripartite guideline S7A. Geneva: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2000.
2. International Council for Harmo-nisation of Technical Requirements for Pharmaceuticals for Human Use. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals: ICH harmonised tri-partite guideline S7B. Geneva: Interna-tional Council for Harmonisation of Technical Requirements for Pharmaceu-ticals for Human Use; 2005.
3. Organisation for Economic Co-operation and Development. OECD principles on Good Laboratory Practice (as revised in 1997). Paris: OECD Publishing; 1998.
4. Organisation for Economic Co-operation and Development. Quality Assurance and GLP. 2nd ed. Paris: OECD Publishing; 2021. 35 p. doihttps://doi.org/10.1787/b37820a3-en.
5. Organisation for Economic Co-operation and Development. The appli-cation of the GLP principles to short-term studies. Paris: OECD Publishing; 2003. 16 p. doihttps://doi.org/10.1787/9789264078659-en.
6. Organisation for Economic Co-operation and Development. GLP data integrity. Paris: OECD Publishing; 2021. 30 p. doihttps://doi.org/10.1787/45779212-en.
7. Organisation for Economic Co-operation and Development. Manage-ment, characterisation and use of test items used in GLP studies. Paris: OECD Publishing; 2018. 20 p. doihttps://doi.org/10.1787/da9ee953-en.
8. Council of the Eurasian Econom-ic Commission. Decision No. 81 of the Council of the Eurasian Economic Commission of 3 November 2016 on approval of the Rules of Good Labora-tory Practice of the Eurasian Economic Union in the field of medicinal products circulation. 2016.
9. Board of the Eurasian Economic Commission. Recommendation No. 18 of the Board of the Eurasian Economic Commission of 27 October 2020 on guidance for pharmacological safety studies of medicinal products for medi-cal use. 2020.
10. GOST R 56700-2015. Medicinal products for medical use. Preclinical pharmacological safety studies. Mos-cow: Standartinform; 2016. (In Russ.)
11. Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. doihttps://doi.org/10.1371/journal.pbio.3000410.
12. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50(4):219-44.
13. Makarova MN, Shubin DV, Makarov VG. Respiratory rate in pre-clinical studies. Laboratornye zhivotnye dlya nauchnykh issledovaniy. 2019;(3). (In Russ.) doihttps://doi.org/10.29296/2618723X-2019-03-03.
14. Eremina NV, Kolik LG, Ostrov-skaya RU, Durnev AD. Preclinical stud-ies of neurotoxic properties of new me-dicinal products in vivo. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya. 2020;10(3):164-76. (In Russ.) doihttps://doi.org/10.30895/1991-2919-2020-10-3-164-176.
15. Morkovin EI, Kurkin DV, Tyurenkov IN. Assessment of psycho-neurological deficit in rodents: basic methods. Zh Vyssh Nerv Deyat Im IP Pavlova. 2018;68(1):3-15. (In Russ.) doihttps://doi.org/10.7868/S004446771801001X.
16. GOST 33044-2014. Principles of Good Laboratory Practice. Moscow: Standartinform; 2015. (In Russ.)
17. Board of the Eurasian Economic Commission. Recommendation No. 33 of the Board of the Eurasian Economic Commission of 14 November 2023 on guidance for work with laboratory (ex-perimental) animals in preclinical (non-clinical) studies. 2023.
18. Grishina AY, Ivkin DY, Na-palkova SM, Buyuklinskaya OV. Func-tioning of the quality assurance system in the study of etmaben pharmacologi-cal safety. Biomeditsina. 2024;20(3):71-4. (In Russ.) doihttps://doi.org/10.33647/2074-5982-20-3-71-74.
19. International Council for Harmo-nisation of Technical Requirements for Pharmaceuticals for Human Use. E14/S7B Questions and Answers: Clini-cal and nonclinical evaluation of QT/QTc interval prolongation and proarrhythmic potential. Geneva: Inter-national Council for Harmonisation of Technical Requirements for Pharmaceu-ticals for Human Use; 2022.
20. Karnakova PK, Komarov TN, Archakova OA, et al. Development and validation of a method for quantitative determination of etmaben in human blood plasma by HPLC-MS/MS. Razrabotka i registratsiya lekarstvennykh sredstv. 2024;13(1):257-71. (In Russ.) doihttps://doi.org/10.33380/2305-2066-2024-13-1-1752.
21. GOST R 51901.12-2007 (IEC 60812:2006). Risk management. Failure mode and effects analysis method. Moscow: Standartinform; 2008. (In Russ.).
